SCHEMBL3239409

SCHEMBL3239409

CC(C)(C(NC(=O)c1ccccc1-c1ccccc1)c1ccccc1)N1CCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLRK1 P26718 2/20 0.46
MICA Q29983 2/20 0.46
RAET1L Q5VY80 2/20 0.46
TSHR P16473 1/20 0.46
RECQL P46063 1/20 0.46
GAA P10253 1/20 0.43
MTTP P55157 7/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
NPY2R P49146 1/20 0.41
CLPP Q16740 2/20 0.40
TACR3 P29371 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230685 0.81 ALDH1A1 (0.44) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL3240602 0.81 SLC6A9 (0.41) KLRK1MICARAET1LTSHRGAA
SCHEMBL3238470 0.81 SLC6A9 (0.46) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL3241918 0.81 ALDH1A1 (0.43) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL3237736 0.81 KCNK3 (0.39) TSHRMEN1KMT2AALDH1A1LMNA
SCHEMBL8266491 0.81 SLC6A9 (0.37) KLRK1MICARAET1LMEN1KMT2A
SCHEMBL3236014 0.80 SLC6A9 (0.47) ALDH1A1
SCHEMBL3241795 0.79 POLB (0.46) ALDH1A1LMNASMN1; SMN2
SCHEMBL3238743 0.79 KMT2A (0.45) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL3240030 0.78 LMNA (0.36) MEN1KMT2AALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
WO-2006067423-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 KLRK1 1993/4885MICA 3076/4885RAET1L 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.